皓元医药(688131) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥240,967,452, representing a 46.88% increase year-over-year[6]. - Net profit attributable to shareholders for Q3 2021 was ¥48,980,850, reflecting a 92.33% increase compared to the same period last year[6]. - The net profit excluding non-recurring items for Q3 2021 was ¥46,481,084, marking a 115.53% increase year-over-year[6]. - Basic and diluted earnings per share for Q3 2021 were both ¥0.66, an increase of 43.48% from the previous year[9]. - Total operating revenue for the first three quarters of 2021 reached ¥696,076,503.61, a significant increase from ¥412,819,198.06 in the same period of 2020, representing a growth of approximately 68.6%[34]. - Net profit for the third quarter of 2021 was ¥143,926,979.85, compared to ¥70,656,124.23 in the third quarter of 2020, indicating an increase of about 103.5%[37]. - Total comprehensive income attributable to the parent company reached CNY 143,826,673.27, compared to CNY 70,413,433.83 in the previous year, reflecting a significant increase[39]. - Basic and diluted earnings per share were both CNY 2.32, up from CNY 1.27 year-over-year[39]. Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥2,166,740,855.55, a 152.87% increase compared to the end of the previous year[9]. - Total current assets reached ¥1,691,370,821.32, compared to ¥636,633,878.93 in the previous year[29]. - Non-current assets totaled ¥475,370,034.23, up from ¥220,209,513.46 at the end of 2020[29]. - Total liabilities amounted to ¥390,006,372.07, up from ¥329,033,685.23, reflecting a growth of approximately 18.5%[32]. - The total non-current liabilities reached ¥222,772,687.29, a significant increase from ¥34,274,413.02, indicating a growth of around 549.5%[32]. - Shareholders' equity amounted to 527,809,707.16, a decrease of 3,763,285.91 from the last reporting period[51]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥20,639,578.34, showing a 12.80% decrease[9]. - Cash inflow from operating activities totaled CNY 721,803,950.77, compared to CNY 435,294,408.47 in the same period last year, indicating a growth of approximately 65.9%[43]. - Cash outflow from operating activities was CNY 701,164,372.43, resulting in a net cash flow from operating activities of CNY 20,639,578.34, down from CNY 23,668,701.86 in the previous year[43]. - The ending balance of cash and cash equivalents was CNY 1,230,868,931.51, up from CNY 218,749,808.02 year-over-year[45]. - The company reported a decrease in cash flow from operating activities compared to the previous year, indicating potential challenges in operational efficiency[43]. Research and Development - The total R&D investment for Q3 2021 was ¥25,798,102.57, up 44.56% year-over-year[9]. - The proportion of R&D investment to revenue was 10.71%, a decrease of 0.17 percentage points compared to the previous year[9]. - Research and development expenses for the third quarter of 2021 were ¥68,923,395.62, compared to ¥46,432,112.01 in the same quarter of 2020, representing an increase of approximately 48.5%[34]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 5,589[18]. - The largest shareholder, Shanghai Anxu Information Technology Co., Ltd., holds 24,480,000 shares, accounting for 32.93% of total shares[21]. - The top ten shareholders include various investment funds, with the largest being China Industrial Bank's mixed securities investment fund holding 1,057,946 shares[21]. Future Plans - The company plans to continue expanding its business and increasing R&D capabilities to support growth[17]. - The company has plans for market expansion and new product development, as indicated by the increase in fixed assets and ongoing projects[29]. - The company is focusing on expanding its market presence and enhancing its product offerings through strategic investments and partnerships[45].